Dataset Information

Combinative in vitro studies and computational model to predict 3D cell migration response to drug insult.

ABSTRACT: The development of drugs to counter diseases related to cell migration has resulted in a multi-billion dollar endeavor. Unfortunately, few drugs have emerged from this effort highlighting the need for new methods to enhance assays to study, analyze and control cell migration. In response to this complex process, computational models have emerged as potent tools to describe migration providing a high throughput and low cost method. However, most models are unable to predict migration response to drug with direct application to in vitro experiments. In addition to this, no model to date has attempted to describe migration in response to drugs while incorporating simultaneously protein signaling, proteolytic activity, and 3D culture. In this paper, we describe an integrated computational approach, in conjunction with in vitro observations, to serve as a platform to accurately predict migration in 3D matrices incorporating the function of matrix metalloproteinases (MMPs) and their interaction with the Extracellular signal-related kinase (ERK) signaling pathway. Our results provide biological insight into how matrix density, MMP activity, integrin adhesions, and p-ERK expression all affect speed and persistence in 3D. Predictions from the model provide insight toward improving drug combinations to more effectively reduce both speed and persistence during migration and the role of integrin adhesions in motility. In this way our integrated platform provides future potential to streamline and improve throughput toward the testing and development of migration targeting drugs with tangible application to current in vitro assays.

SUBMITTER: Maffei JS

PROVIDER: S-EPMC4172491 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Combinative in vitro studies and computational model to predict 3D cell migration response to drug insult.

Maffei Joseph S JS Srivastava Jaya J Fallica Brian B Zaman Muhammad H MH

Integrative biology : quantitative biosciences from nano to macro 20141001 10

The development of drugs to counter diseases related to cell migration has resulted in a multi-billion dollar endeavor. Unfortunately, few drugs have emerged from this effort highlighting the need for new methods to enhance assays to study, analyze and control cell migration. In response to this complex process, computational models have emerged as potent tools to describe migration providing a high throughput and low cost method. However, most models are unable to predict migration response to ...[more]

PMID: 25174457

Similar Datasets

Project description:BACKGROUND AND OBJECTIVES:Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug-drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies. METHODS:In vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters. A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide. Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, organic anion-transporting polypeptide (OATP)1B1, OATP1B3 and organic anion transporter (OAT)3]. RESULTS:In vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP. The enzymatic activity of nine CYP isoforms was not inhibited or slightly inhibited in vitro with darolutamide, and a rank order and mechanistic static assessment indicated that risk of clinically relevant DDIs via CYP inhibition is very low. In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity. Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was observed in vitro. Phase I data showed that darolutamide exposure increased 1.75-fold with co-administered itraconazole and decreased by 72% with rifampicin. Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects. Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition. CONCLUSIONS:Darolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note.

Project description:In recent years, the integration of 'omics' technologies, high performance computation, and mathematical modeling of biological processes marks that the systems biology has started to fundamentally impact the way of approaching drug discovery. The LINCS public data warehouse provides detailed information about cell responses with various genetic and environmental stressors. It can be greatly helpful in developing new drugs and therapeutics, as well as improving the situations of lacking effective drugs, drug resistance and relapse in cancer therapies, etc.In this study, we developed a Ternary status based Integer Linear Programming (TILP) method to infer cell-specific signaling pathway network and predict compounds' treatment efficacy. The novelty of our study is that phosphor-proteomic data and prior knowledge are combined for modeling and optimizing the signaling network. To test the power of our approach, a generic pathway network was constructed for a human breast cancer cell line MCF7; and the TILP model was used to infer MCF7-specific pathways with a set of phosphor-proteomic data collected from ten representative small molecule chemical compounds (most of them were studied in breast cancer treatment). Cross-validation indicated that the MCF7-specific pathway network inferred by TILP were reliable predicting a compound's efficacy. Finally, we applied TILP to re-optimize the inferred cell-specific pathways and predict the outcomes of five small compounds (carmustine, doxorubicin, GW-8510, daunorubicin, and verapamil), which were rarely used in clinic for breast cancer. In the simulation, the proposed approach facilitates us to identify a compound's treatment efficacy qualitatively and quantitatively, and the cross validation analysis indicated good accuracy in predicting effects of five compounds.In summary, the TILP model is useful for discovering new drugs for clinic use, and also elucidating the potential mechanisms of a compound to targets.

Dataset Information

Combinative in vitro studies and computational model to predict 3D cell migration response to drug insult.

Publications

Combinative in vitro studies and computational model to predict 3D cell migration response to drug insult.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure